Newsoara Biopharma Co., Ltd.
11
4
4
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
9.1%
1 terminated/withdrawn out of 11 trials
50.0%
-36.5% vs industry average
9%
1 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Role: collaborator
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants
Role: lead
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants
Role: lead
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Role: collaborator
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Role: collaborator
HPP737 Substance Balance Study in Human
Role: lead
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
Role: lead
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
Role: lead
Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM
Role: lead
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus
Role: lead
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
Role: lead
All 11 trials loaded